A costing study of bortezomib shows equivalence of its real-world costs to conventional treatment

Br J Haematol. 2020 May;189(3):e76-e79. doi: 10.1111/bjh.16484. Epub 2020 Jan 31.

Authors

Jane F Thompson¹, Zoe Teh², Yiyang Chen³, Joanne Gardiner⁴, Jana M Bednarz⁵, Geoffrey N Thompson⁵, Cindy Lee⁴, Noemi Horvath⁴, Peter Bardy¹, David Yeung⁴

Affiliations

¹ Haematology Department, Royal Adelaide Hospital, Adelaide, Australia.
² General Medicine, Royal Adelaide Hospital, Adelaide, Australia.
³ Intern, Royal Adelaide Hospital, Adelaide, Australia.
⁴ Royal Adelaide Hospital, Adelaide, Australia.
⁵ University of Adelaide, Adelaide, Australia.

PMID: 32004380
DOI: 10.1111/bjh.16484

No abstract available

Keywords: bortezomib; cost of illness; economics; haematologic diseases; medical; myeloma; novel agents; real-world.

Publication types

Letter

MeSH terms

Antineoplastic Agents / economics*
Antineoplastic Agents / therapeutic use
Bortezomib / economics*
Bortezomib / therapeutic use
Cost-Benefit Analysis / methods*
Female
Humans
Male
Multiple Myeloma / drug therapy*

Substances

Antineoplastic Agents
Bortezomib